King-Friend Industrial, a biopharmaceutical enterprise, agreed to acquire YUSIMRY from Coherus BioSciences, a commercial-stage biopharmaceutical company, for $40m. “With the divesture of YUSIMRY, Coherus reinforces its strategic focus on oncology. The proceeds from the sale of YUSIMRY will bolster our cash position, advance our efforts to become a sustainable and growing oncology company and efficiently allocate our resources for maximum value creation," Denny Lanfear, Coherus Chairman and CEO.